{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:28:50Z","timestamp":1789000130040,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ebiom.2021.103811","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T02:24:57Z","timestamp":1642213497000},"page":"103811","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1\/2 randomised, double-blind, placebo-controlled, dose-ranging trial"],"prefix":"10.1016","volume":"75","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Vanhoutte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1069-466X","authenticated-orcid":false,"given":"Richard T.","family":"Wiedmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth","family":"Haspeslagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Boundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Aliprantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2830-2396","authenticated-orcid":false,"given":"Michelle","family":"Davila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Hartzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mac","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Ramsauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Tomberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Tschismarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5725-558X","authenticated-orcid":false,"given":"Jeffrey R.","family":"Sachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1317-3819","authenticated-orcid":false,"given":"Kevin","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Aubrey","family":"Stoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5141-3452","authenticated-orcid":false,"given":"Eseng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2021.103811_bib0001","unstructured":"World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 17 May 2021 2021. https:\/\/covid19.who.int\/."},{"key":"10.1016\/j.ebiom.2021.103811_bib0002","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.3389\/fimmu.2020.583077","article-title":"Emerging concepts and technologies in vaccine development","volume":"11","author":"Brisse","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.ebiom.2021.103811_bib0003","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1021\/acsinfecdis.0c00646","article-title":"Recent insights into emerging coronavirus: SARS-CoV-2","volume":"7","author":"Shang","year":"2020","journal-title":"ACS Infectious Dis"},{"key":"10.1016\/j.ebiom.2021.103811_bib0004","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1016\/j.csbj.2021.04.061","article-title":"An overview of current COVID-19 vaccine platforms","volume":"19","author":"Nagy","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.ebiom.2021.103811_bib0005","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ijid.2021.01.035","article-title":"Pharmacological strategies to prevent SARS-CoV-2 infection and to treat the early phases of COVID-19 disease","volume":"104","author":"Scarabel","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"21","key":"10.1016\/j.ebiom.2021.103811_bib0006","doi-asserted-by":"crossref","first-page":"11546","DOI":"10.1128\/JVI.77.21.11546-11554.2003","article-title":"A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice","volume":"77","author":"Combredet","year":"2003","journal-title":"J Virol"},{"issue":"10165","key":"10.1016\/j.ebiom.2021.103811_bib0007","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/S0140-6736(18)32488-7","article-title":"Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial","volume":"392","author":"Reisinger","year":"2018","journal-title":"Lancet North Am Ed"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103811_bib0008","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/infdis\/jis328","article-title":"Measles vaccine expressing the secreted form of West Nile virus envelope glycoprotein induces protective immunity in squirrel monkeys, a new model of West Nile virus infection","volume":"206","author":"Brandler","year":"2012","journal-title":"J Infect Dis"},{"issue":"36","key":"10.1016\/j.ebiom.2021.103811_bib0009","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1016\/j.vaccine.2013.05.086","article-title":"A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus","volume":"31","author":"Brandler","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103811_bib0010","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1128\/JVI.78.1.146-157.2004","article-title":"A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV","volume":"78","author":"Lorin","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.ebiom.2021.103811_bib0011","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.virol.2018.05.028","article-title":"Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model","volume":"521","author":"Bodmer","year":"2018","journal-title":"Virology"},{"issue":"11","key":"10.1016\/j.ebiom.2021.103811_bib0012","doi-asserted-by":"crossref","first-page":"e50397","DOI":"10.1371\/journal.pone.0050397","article-title":"Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine","volume":"7","author":"Stebbings","year":"2012","journal-title":"PLoS One"},{"issue":"512","key":"10.1016\/j.ebiom.2021.103811_bib0013","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw3163","article-title":"Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot","volume":"11","author":"Mateo","year":"2019","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103811_bib0014","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01485-18","article-title":"A measles virus-based vaccine candidate mediates protection against Zika virus in an allogeneic mouse pregnancy model","volume":"93","author":"N\u00fcrnberger","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.ebiom.2021.103811_bib0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.virol.2014.01.002","article-title":"Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein","volume":"452","author":"Escriou","year":"2014","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103811_bib0016","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial","volume":"15","author":"Ramsauer","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2021.103811_bib0017","article-title":"Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 \/TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study","author":"Launay","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ebiom.2021.103811_bib0018","unstructured":"U.S. Food & Drug Administration. Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. 2007. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical (accessed 25 May 2021)."},{"key":"10.1016\/j.ebiom.2021.103811_bib0019","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1038\/s41596-021-00536-y","article-title":"Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays","volume":"16","author":"Bewley","year":"2021","journal-title":"Nat Protoc"},{"issue":"559","key":"10.1016\/j.ebiom.2021.103811_bib0020","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc3103","article-title":"A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations","volume":"12","author":"Grzelak","year":"2020","journal-title":"Sci Transl Med"},{"issue":"10275","key":"10.1016\/j.ebiom.2021.103811_bib0021","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet North Am Ed"},{"issue":"10267","key":"10.1016\/j.ebiom.2021.103811_bib0022","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"Lancet North Am Ed"},{"issue":"19","key":"10.1016\/j.ebiom.2021.103811_bib0023","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1\u20132a Trial of Ad26. COV2. S Covid-19 Vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2021.103811_bib0024","article-title":"Cross-species translation of correlates of protection for COVID-19 vaccine candidates using quantitative tools. ID Week","author":"Largajolli","year":"2021","journal-title":"Virtual"},{"key":"10.1016\/j.ebiom.2021.103811_bib0025","first-page":"1","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.ebiom.2021.103811_bib0026","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ebiom.2021.103811_bib0027","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"10249","key":"10.1016\/j.ebiom.2021.103811_bib0028","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet North Am Ed"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396421006058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396421006058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:12:49Z","timestamp":1762456369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396421006058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":28,"alternative-id":["S2352396421006058"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103811","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1\/2 randomised, double-blind, placebo-controlled, dose-ranging trial","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103811","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA and The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103811"}}